Agilent CLO DiMarco to Exit by September in Executive Transition
Agilent Technologies (NYSE: A) announced a significant leadership change on April 3, 2026, with Chief Legal Officer Bret DiMarco set to depart his role by September 30, as the life sciences and diagnostics company begins searching for his replacement.
The Change
DiMarco, who currently serves as Senior Vice President, Chief Legal Officer and Secretary, signed a transition agreement on March 31, 2026, that establishes a structured departure timeline. He will resign from his executive positions upon the earlier of two events: when a new Chief Legal Officer starts or September 30, 2026.
The transition plan includes DiMarco continuing as a Special Advisor through December 1, 2026, to ensure a smooth handover of responsibilities. During this advisory period, he will receive an annualized base salary of $350,000 and maintain his health benefits and equity vesting rights, though he will not receive new equity grants or be eligible for the 2026 annual bonus.
Following his advisory service and subject to executing a supplemental release of claims, DiMarco will receive a lump sum payment calculated as one times his current base salary plus target bonus, minus the compensation received during his Special Advisor role. This structured exit package ensures both continuity for Agilent and appropriate compensation for DiMarco's transition assistance.
Background
As Chief Legal Officer, DiMarco has overseen Agilent's legal affairs, corporate governance, and regulatory compliance for the $6.8 billion revenue company that employs approximately 18,000 people globally. Agilent, headquartered in Santa Clara, California, provides laboratories worldwide with instruments, services, consumables, applications and expertise in life sciences, diagnostics and applied chemical markets.
The company operates in highly regulated industries where legal expertise is crucial for navigating complex international compliance requirements, intellectual property matters, and strategic transactions. DiMarco's role has been particularly important as Agilent has pursued its strategy of focusing on higher-growth end markets while divesting non-core assets.
The timing of this transition comes as Agilent continues to execute under CEO Padraig McDonnell's leadership, who signed the SEC filing announcing DiMarco's departure. The company has been navigating challenging market conditions in recent quarters, with particular softness in China and pharmaceutical end markets affecting growth rates.
What It Means
This executive transition signals Agilent's commitment to orderly succession planning, with a six-month window to identify and onboard a new Chief Legal Officer. The extended timeline suggests the company is prioritizing finding the right candidate rather than rushing to fill the position, which is critical given the complex regulatory environment in which Agilent operates.
The structured transition agreement, with DiMarco remaining as Special Advisor through December, should minimize disruption to ongoing legal matters and strategic initiatives. This approach allows for knowledge transfer and maintains continuity in legal operations during what could be a critical period for the company as it works to return to growth following recent market challenges.
For investors, the departure of a senior executive like the Chief Legal Officer warrants attention, though the orderly nature of this transition and the clear succession timeline should alleviate concerns about operational disruption. The company's decision to maintain DiMarco in an advisory capacity demonstrates prudent risk management and suggests confidence in executing a smooth leadership change.
The financial terms of the transition, including the continued vesting of equity awards and the structured exit payment, appear designed to incentivize DiMarco's cooperation through the transition period while being mindful of shareholder interests. This balanced approach reflects standard practice for executive transitions at major public companies.
As Agilent begins its search for a new Chief Legal Officer, the appointee will inherit responsibility for legal strategy at a company facing both challenges and opportunities in evolving life sciences markets. The new CLO will need expertise in international operations, M&A transactions, and regulatory compliance across multiple jurisdictions.
*Source: SEC Form 8-K filed by Agilent Technologies on April 3, 2026*
*StockCliff Research*